Last reviewed · How we verify
Prophylaxis A
At a glance
| Generic name | Prophylaxis A |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Screening and Multiple Intervention on Lung Epidemics (PHASE2)
- A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer (PHASE2)
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- A Self-management Program to Prevent Falls in People With Multiple Sclerosis (NA)
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES) (NA)
- Pharmacy-based PrEP Delivery in Kenya (NA)
- PRACOH Prevention Breakdown Support Advice Guidance Disability (NA)
- Adaptation and Implementation of an Evidence-based Approach to Advance HIV Prevention and Care (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prophylaxis A CI brief — competitive landscape report
- Prophylaxis A updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI